Details of the Drug

General Information of Drug (ID: DML5VQ0)

• Drug Name: Fenoprofen
• Synonyms: Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Approved	[1]
Pain	MG30-MG3Z	Approved	[1]
Rheumatoid arthritis	FA20	Approved	[2]

• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 242.27
  Logarithm of the Partition Coefficient (xlogp); 3.3
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.6 mL/min/kg [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 206.37532 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.1 L/kg [4]
• Chemical Identifiers:
  Formula: C15H14O3
  IUPAC Name: 2-(3-phenoxyphenyl)propanoic acid
  Canonical SMILES: CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
  InChI: InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
  InChIKey: RDJGLLICXDHJDY-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3342
  ChEBI ID: CHEBI:5004
  CAS Number: 29679-58-1
  DrugBank ID: DB00573
  TTD ID: D03XYW
  ACDINA ID: D00270
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Inhibitor	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[7]
Dehydrogenase/reductase SDR family member 11 (DHRS11)	OTU3J0ZL	DHR11_HUMAN	Gene/Protein Processing	[8]
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1)	OT7OG7Y2	DPA1_HUMAN	Gene/Protein Processing	[9]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Gene/Protein Processing	[9]
Prostaglandin reductase 1 (PTGR1)	OTMAR351	PTGR1_HUMAN	Gene/Protein Processing	[10]
Tumor necrosis factor receptor superfamily member 16 (NGFR)	OTPKSM49	TNR16_HUMAN	Gene/Protein Processing	[6]
UDP-glucuronosyltransferase 1A10	OTOTZVEY	UD110_HUMAN	Biotransformations	[11]
UDP-glucuronosyltransferase 1A3	OTUEOER3	UD13_HUMAN	Biotransformations	[11]
UDP-glucuronosyltransferase 1A7	OTY4JJ32	UD17_HUMAN	Biotransformations	[11]
UDP-glucuronosyltransferase 1A8	OTTMABBG	UD18_HUMAN	Biotransformations	[11]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fenoprofen

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Sulfasalazine.	Rheumatoid arthritis [FA20]	[12]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Dexamethasone.	Rheumatoid arthritis [FA20]	[13]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Fenoprofen and Leflunomide.	Rheumatoid arthritis [FA20]	[14]

Coadministration of a Drug Treating the Disease Different from Fenoprofen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[15]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Repaglinide.	Acute diabete complication [5A2Y]	[16]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Glibenclamide.	Acute diabete complication [5A2Y]	[16]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Tolazamide.	Acute diabete complication [5A2Y]	[16]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Nateglinide.	Acute diabete complication [5A2Y]	[16]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Glipizide.	Acute diabete complication [5A2Y]	[16]
Inotersen	DMJ93CT	Major	Increased risk of bleeding by the combination of Fenoprofen and Inotersen.	Amyloidosis [5D00]	[17]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Methylphenobarbital	DMDSWAG	Minor	Increased metabolism of Fenoprofen caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[19]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Cilostazol.	Arterial occlusive disease [BD40]	[20]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Budesonide.	Asthma [CA23]	[13]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Kanamycin.	Bacterial infection [1A00-1C4Z]	[22]
Trovafloxacin	DM6AN32	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Streptomycin.	Bacterial infection [1A00-1C4Z]	[22]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Fenoprofen and ABT-492.	Bacterial infection [1A00-1C4Z]	[21]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Gentamicin.	Bacterial infection [1A00-1C4Z]	[22]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Netilmicin.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Tobramycin.	Bacterial infection [1A00-1C4Z]	[22]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Etidronic acid.	Bone paget disease [FB85]	[23]
Risedronate	DM5FLTY	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Risedronate.	Bone paget disease [FB85]	[23]
Alendronate	DMY2KX9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Alendronate.	Bone paget disease [FB85]	[23]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Fenoprofen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[24]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Fenoprofen and Iodipamide.	Cholelithiasis [DC11]	[25]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Levomilnacipran.	Chronic pain [MG30]	[26]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Fenoprofen and Regorafenib.	Colorectal cancer [2B91]	[17]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Fenoprofen and Drospirenone.	Contraceptive management [QA21]	[27]
Thiopental	DMGP8AX	Minor	Increased metabolism of Fenoprofen caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[19]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Methoxyflurane.	Corneal disease [9A76-9A78]	[17]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Fenoprofen and Ardeparin.	Coronary thrombosis [BA43]	[28]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Fenoprofen and Danaparoid.	Deep vein thrombosis [BD71]	[28]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Fenoprofen and Rivaroxaban.	Deep vein thrombosis [BD71]	[29]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Vilazodone.	Depression [6A70-6A7Z]	[26]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Paroxetine.	Depression [6A70-6A7Z]	[26]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Vortioxetine.	Depression [6A70-6A7Z]	[26]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Milnacipran.	Depression [6A70-6A7Z]	[26]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Escitalopram.	Depression [6A70-6A7Z]	[26]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Desvenlafaxine.	Depression [6A70-6A7Z]	[26]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Clomipramine.	Depression [6A70-6A7Z]	[26]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Fenoprofen and PMID28870136-Compound-49.	Discovery agent [N.A.]	[30]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[26]
Primidone	DM0WX6I	Minor	Increased metabolism of Fenoprofen caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Fenoprofen caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Cannabidiol.	Epileptic encephalopathy [8A62]	[17]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Fenoprofen when combined with Ethacrynic acid.	Essential hypertension [BA00]	[31]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Tazemetostat.	Follicular lymphoma [2A80]	[20]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Fenoprofen and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Sulfinpyrazone.	Gout [FA25]	[20]
Eplerenone	DMF0NQR	Moderate	Antagonize the effect of Fenoprofen when combined with Eplerenone.	Heart failure [BD10-BD1Z]	[32]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Fenoprofen when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[31]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Fenoprofen when combined with Furosemide.	Heart failure [BD10-BD1Z]	[31]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Fenoprofen when combined with Amiloride.	Heart failure [BD10-BD1Z]	[31]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Fenoprofen when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[31]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[33]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Fenoprofen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[35]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Fenoprofen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[14]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Fenoprofen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[36]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Fenoprofen when combined with Indapamide.	Hypertension [BA00-BA04]	[31]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Fenoprofen when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[31]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Fenoprofen when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[31]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Dipyridamole.	Hypertension [BA00-BA04]	[20]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Fenoprofen and Potassium chloride.	Hypo-kalaemia [5C77]	[37]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Balsalazide.	Indeterminate colitis [DD72]	[12]
Amobarbital	DM0GQ8N	Minor	Increased metabolism of Fenoprofen caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[19]
Ibandronate	DM0QZBN	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Ibandronate.	Low bone mass disorder [FB83]	[17]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Fenoprofen and Porfimer Sodium.	Lung cancer [2C25]	[38]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[39]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Idelalisib.	Mature B-cell leukaemia [2A82]	[40]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Fenoprofen and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[41]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Clofarabine.	Mature B-cell lymphoma [2A85]	[17]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Fenoprofen and Ibrutinib.	Mature B-cell lymphoma [2A85]	[42]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Fenoprofen and Ponatinib.	Mature B-cell lymphoma [2A85]	[43]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Fenoprofen and Exjade.	Mineral absorption/transport disorder [5C64]	[44]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Fenoprofen and Panobinostat.	Multiple myeloma [2A83]	[15]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Deflazacort.	Muscular dystrophy [8C70]	[13]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[20]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Fenoprofen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[45]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Fenoprofen and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[46]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Fenoprofen and Prasugrel.	Myocardial infarction [BA41-BA43]	[17]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Fenoprofen and Vorapaxar.	Myocardial infarction [BA41-BA43]	[47]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Tirofiban.	Myocardial infarction [BA41-BA43]	[48]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Sibutramine.	Obesity [5B80-5B81]	[26]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Dexfenfluramine.	Obesity [5B80-5B81]	[26]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Fenoprofen when combined with Polythiazide.	Oedema [MG29]	[31]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Diclofenac.	Osteoarthritis [FA00-FA05]	[49]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Fenoprofen and MK-4827.	Ovarian cancer [2C73]	[17]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Aspirin.	Pain [MG30-MG3Z]	[50]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Prednisone.	Postoperative inflammation [1A00-CA43]	[13]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[13]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Epoprostenol.	Pulmonary hypertension [BB01]	[51]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Iloprost.	Pulmonary hypertension [BB01]	[51]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Fenoprofen and Everolimus.	Renal cell carcinoma [2C90]	[52]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Fenoprofen and Temsirolimus.	Renal cell carcinoma [2C90]	[52]
Gatifloxacin	DMSL679	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[21]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[13]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Pitolisant.	Somnolence [MG42]	[17]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Fenoprofen and Naltrexone.	Substance abuse [6C40]	[53]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Caplacizumab.	Thrombocytopenia [3B64]	[20]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Fenoprofen and Apixaban.	Thrombosis [DB61-GB90]	[17]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Cangrelor.	Thrombosis [DB61-GB90]	[20]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Fenoprofen and Brilinta.	Thrombosis [DB61-GB90]	[17]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Fenoprofen and Cabozantinib.	Thyroid cancer [2D10]	[54]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Fenoprofen and Sirolimus.	Transplant rejection [NE84]	[52]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Fenoprofen and Tacrolimus.	Transplant rejection [NE84]	[52]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[16]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Fenoprofen and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[16]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Olsalazine.	Ulcerative colitis [DD71]	[12]
Cinoxacin	DM4EWNS	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Cinoxacin.	Urinary tract infection [GC08]	[21]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Fenoprofen and Plazomicin.	Urinary tract infection [GC08]	[22]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS depression effects by the combination of Fenoprofen and Nalidixic acid.	Urinary tract infection [GC08]	[21]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[13]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Fenoprofen and Betrixaban.	Venous thromboembolism [BD72]	[55]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Colcothar yellow	E00436	518696	Colorant
Haematite red	E00236	14833	Colorant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fenoprofen 600 mg tablet	600 mg	Oral Tablet	Oral
Fenoprofen 400 mg capsule	400 mg	Oral Capsule	Oral
Fenoprofen 200 mg capsule	200 mg	Oral Capsule	Oral
Fenoprofen Calcium eq 400mg base capsule	eq 400mg base	Capsule	Oral
Fenoprofen Calcium eq 200mg base capsule	eq 200mg base	Capsule	Oral
Fenoprofen Calcium eq 300mg base capsule	eq 300mg base	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Fenoprofen FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4820).
• [3] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
• [7] A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
• [8] Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
• [9] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [10] Human prostaglandin reductase 1 (PGR1): Substrate specificity, inhibitor analysis and site-directed mutagenesis. Chem Biol Interact. 2015 Jun 5;234:105-13.
• [11] Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem. 2004 Jul 2;279(27):28320-9. doi: 10.1074/jbc.M401396200. Epub 2004 Apr 26.
• [12] Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
• [13] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
• [14] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [17] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [18] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [19] Helleberg L, Rubin A, Wolen RL, et al "A pharmacokinetic interaction in man between phenobarbitone and fenoprofen, a new anti-inflammatory agent." Br J Clin Pharmacol 1 (1974): 371-4. [PMID: 22454912]
• [20] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [21] Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
• [22] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
• [23] Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
• [24] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [25] Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
• [26] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [27] Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
• [28] Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
• [29] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [30] Canadian Pharmacists Association.
• [31] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
• [32] Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
• [33] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [34] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [35] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [36] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [37] Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
• [38] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [39] Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
• [40] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [41] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [42] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [43] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [44] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [45] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [46] Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
• [47] Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
• [48] Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
• [49] Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
• [50] Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
• [51] Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
• [52] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [53] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [54] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
• [55] Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.